Trevor Feinstein

464 total citations
27 papers, 248 citations indexed

About

Trevor Feinstein is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Trevor Feinstein has authored 27 papers receiving a total of 248 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Trevor Feinstein's work include Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Trevor Feinstein is often cited by papers focused on Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Trevor Feinstein collaborates with scholars based in United States, Japan and China. Trevor Feinstein's co-authors include Athanassios Argiris, Jennifer R. Grandis, William E. Gooding, Robert L. Ferris, Barton F. Branstetter, Lin Wang, Sujith Kalmadi, Raja R. Seethala, Sufi M. Thomas and Steve Lee and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Trevor Feinstein

25 papers receiving 243 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Trevor Feinstein United States 8 166 73 55 53 52 27 248
Astrid De Meulenaere Belgium 10 261 1.6× 75 1.0× 49 0.9× 65 1.2× 40 0.8× 16 329
Yunjian Huang China 9 217 1.3× 182 2.5× 65 1.2× 69 1.3× 73 1.4× 30 345
Grégoire Marret France 8 119 0.7× 74 1.0× 96 1.7× 27 0.5× 48 0.9× 24 231
Aaron E. Sosa Spain 8 194 1.2× 84 1.2× 85 1.5× 31 0.6× 30 0.6× 13 275
Beatriz García-Paredes Spain 9 177 1.1× 67 0.9× 37 0.7× 54 1.0× 55 1.1× 18 250
Daiyuan Ma China 10 139 0.8× 110 1.5× 77 1.4× 60 1.1× 55 1.1× 40 274
Jim Vasselli United States 8 365 2.2× 121 1.7× 34 0.6× 47 0.9× 23 0.4× 10 406
Virginia Palomar Coloma France 4 421 2.5× 190 2.6× 42 0.8× 65 1.2× 48 0.9× 5 481
Xiao Hu China 9 127 0.8× 118 1.6× 77 1.4× 72 1.4× 58 1.1× 33 267
Danilo Galizia Italy 10 179 1.1× 108 1.5× 58 1.1× 26 0.5× 68 1.3× 32 285

Countries citing papers authored by Trevor Feinstein

Since Specialization
Citations

This map shows the geographic impact of Trevor Feinstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Trevor Feinstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Trevor Feinstein more than expected).

Fields of papers citing papers by Trevor Feinstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Trevor Feinstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Trevor Feinstein. The network helps show where Trevor Feinstein may publish in the future.

Co-authorship network of co-authors of Trevor Feinstein

This figure shows the co-authorship network connecting the top 25 collaborators of Trevor Feinstein. A scholar is included among the top collaborators of Trevor Feinstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Trevor Feinstein. Trevor Feinstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Aushev, Vasily N., Joe Ensor, Stephanie Sanchez, et al.. (2025). Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort.. Journal of Clinical Oncology. 43(4_suppl). 15–15. 2 indexed citations
3.
Muro, Kei, Trevor Feinstein, Joaquina Baranda, et al.. (2024). Enfortumab vedotin (EV) in non-squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202.. Journal of Clinical Oncology. 42(16_suppl). 8585–8585. 2 indexed citations
4.
Kasi, Pashtoon Murtaza, Vasily N. Aushev, Joe Ensor, et al.. (2024). Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.. Journal of Clinical Oncology. 42(3_suppl). 9–9. 37 indexed citations
5.
6.
7.
Feinstein, Trevor, Stephan Ogenstad, Dominic Mitchell, Lan Huang, & Ramon Mohanlal. (2022). DUBLIN-3 results on quality of life (QoL) in second/third-line EGFR-wild type NSCLC patients (pts) receiving docetaxel (Doc) with or without plinabulin (Plin) using the validated EORTC QLQ C30 and QLQ LC13 questionnaires.. Journal of Clinical Oncology. 40(16_suppl). 9091–9091. 3 indexed citations
8.
Ono, Makiko, Justine Y. Bruce, Trevor Feinstein, et al.. (2022). Abstract OT1-02-04: Enfortumab vedotin 202: Phase 2 study of enfortumab vedotin for previously treated advanced solid tumors, including breast cancer. Cancer Research. 82(4_Supplement). OT1–2. 2 indexed citations
9.
Cynthia, X., Pat W. Whitworth, Svetislava J. Vukelja, et al.. (2022). FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data.. Journal of Clinical Oncology. 40(16_suppl). TPS612–TPS612. 1 indexed citations
10.
11.
12.
Mohanlal, Ramon, Yongkun Sun, Goetz Kloecker, et al.. (2019). P2.01-23 DUBLIN-3, a Phase (Ph) III Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone in Stage IIIb/IV NSCLC. Journal of Thoracic Oncology. 14(10). S647–S648. 6 indexed citations
13.
Feinstein, Trevor, Stephen Y. Lai, Diana Lenzner, et al.. (2011). Prognostic factors in patients with high‐risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy. Head & Neck. 33(3). 318–323. 34 indexed citations
14.
Argiris, Athanassios, Steve Lee, Trevor Feinstein, et al.. (2011). Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncology. 47(10). 961–966. 42 indexed citations
15.
Argiris, Athanassios, Trevor Feinstein, Lin Wang, et al.. (2011). Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Investigational New Drugs. 30(4). 1575–1584. 17 indexed citations
16.
Feinstein, Trevor, Sachin Agrawal, Ronald G. Stoller, Merrill J. Egorin, & Athanassios Argiris. (2009). Phase I and pharmacokinetic (PK) study of dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies. Journal of Clinical Oncology. 27(15_suppl). 3540–3540. 6 indexed citations
17.
Ferris, Robert L., Trevor Feinstein, Jennifer R. Grandis, et al.. (2009). Serum biomarkers as predictors of clinical outcome after cetuximab-based therapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology. 27(15_suppl). 6035–6035. 3 indexed citations
18.
Feinstein, Trevor, Michael K. Gibson, P. Savvides, et al.. (2008). Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): updated results of a phase II trial. Journal of Clinical Oncology. 26(15_suppl). 6069–6069. 13 indexed citations
19.
Chatta, Gurkamal, Trevor Feinstein, Leonard J. Appleman, et al.. (2008). Oxaliplatin and docetaxel in castration-resistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: Updated results of a phase II trial. Journal of Clinical Oncology. 26(15_suppl). 5148–5148. 5 indexed citations
20.
Feinstein, Trevor, et al.. (2007). A phase II trial of oxaliplatin and docetaxel in patients with androgen independent prostate cancer (AIPC) who have progressed to two prior regimens of chemotherapy. Journal of Clinical Oncology. 25(18_suppl). 15545–15545. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Astrid De Meulenaere Breakdown of academic impact, for papers by Yunjian Huang Breakdown of academic impact, for papers by Grégoire Marret Breakdown of academic impact, for papers by Aaron E. Sosa Breakdown of academic impact, for papers by Beatriz García-Paredes Breakdown of academic impact, for papers by Daiyuan Ma Breakdown of academic impact, for papers by Jim Vasselli Breakdown of academic impact, for papers by Virginia Palomar Coloma Breakdown of academic impact, for papers by Xiao Hu Breakdown of academic impact, for papers by Danilo Galizia
Rankless by CCL
2026